



This monograph was prepared by The Ottawa Integrative Cancer Centre (OICC), in collaboration with the Complementary Medicine Education and Outcomes (CAMEO) Research Program. It is part of a series of monographs being developed to share results of a review of the research evidence related to common therapies and products used within cancer patient care.

The following monograph is designed to summarize evidence-based research and does not advocate for or against the use of a particular therapy. Every effort is made to ensure the information included in this monograph is accurate at the time it is published.

Please note that this monograph does not include an exhaustive list of all potential adverse events; individuals may experience unique side effects. The information in this monograph should not be interpreted as medical advice nor should it replace the advice of a licensed health care provider. Prior to using a new therapy or product, always consult a licensed health care provider.

For the safe use of natural health products, please consider the following:

- Consult a licensed health care provider prior to using a natural health product and make a plan to monitor its effectiveness and any side effects. This is particularly important for pregnant or breast-feeding women and people with serious medical conditions.
 - To help prevent interactions with your prescribed medication, ensure your health care provider is aware of any drugs or natural health products you may be using. Make sure to note all natural health ingredients listed in compound products.
 - Read and follow all instructions on the product label.
- If purchasing natural health products in Canada, look for Health Canada approved products. Look for Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM) on the label to identify licensed products. Avoid internet pharmacies, as the quality of products cannot be guaranteed and products might not be licensed for sale through Health Canada. For more information, visit <http://www.hc-sc.gc.ca/dhp-mpps/prodnatur/about-apropos/cons-eng.php>

Please note: While the aim was to draw from the most extensive research, in some circumstances the information used was limited by the selection and caliber of available research studies. Full references are available in the corresponding full-length monographs found on the CAMEO website.

Disclaimer

The OICC, in collaboration with the CAMEO Research Program, has prepared this monograph, as part of a series of monograph development, to share results of a review of the research evidence related to common therapies and products used within cancer patient care. The following monograph is designed to provide evidence-based research and neither advocates for or against the use of a particular therapy. Every effort is made to ensure the information included in this monograph is accurate at the time it is published. Prior to using a new therapy or product, always consult a licensed health care provider. The information in this monograph should not be interpreted as medical advice nor should it replace the advice of a qualified health care provider.



BLACK COHOSH

Proper Name

Actea racemosa; *Cimicifuga racemosa*

Common Name

Black cohosh; *Black snake root*; *Black bugbane*

*Note: Black cohosh is **not** the same as Blue cohosh (Caulophyllum thalictroides)*

Proprietary Extracts

Remifemin; Klimadynon; CimiPure

Common Uses in Cancer Care

Management of hot flashes secondary to treatment with hormonal therapies or the early onset of menopause.

Route of Administration

Oral

Mechanism of Action

The mechanism of action of black cohosh is not well defined. Black cohosh does not appear to increase circulating estrogen levels or exert estrogenic effects on breast tissue, the endometrium, or vaginal tissue. Black cohosh may exert estrogenic effects on bone. Black cohosh may possess selective estrogen receptor modulating effects (1, 2). Alternately, black cohosh may act through serotonergic effects (3) and/or through modulation of the hypothalamic thermoregulatory centers (1, 2).

Clinical Evidence related to Effectiveness for Hot Flashes

Based on 1 cohort study, 2 uncontrolled trials, and 3 RCTs, there is mixed evidence regarding the efficacy of black cohosh in the management of hot flashes in breast cancer patients.

Of the RCTs, two showed reductions in hot flash score or Green Climacteric Scale (GCS) compared to baseline in the black cohosh group; however similar improvements were seen in the control groups also, so there was no statistically significant difference when black cohosh was compared to placebo (4, 5). In these studies, some of the women were also on tamoxifen, but these women were equally distributed between the black cohosh and the placebo groups.

One open label RCT assessing the effect of tamoxifen plus black cohosh compared to tamoxifen alone showed a large improvement in the black cohosh group, with 46% of women in the black cohosh group reporting no hot flashes, compared to 0% of women in the control group reporting no hot flashes (p value not reported) (6). However this was an unblinded study with higher risk of expectation bias.

Of 2 uncontrolled trials, both reported significant improvements in measures of hot flashes (hot flash score, hot flash severity, Menopause Rating Scale-II) compared to baseline (7, 8). In one of these studies all the patients were also receiving between 10-40mg tamoxifen (8), while in the other study 29% of patients were on either tamoxifen or an aromatase inhibitor (7).

One cohort study found no association between black cohosh use and quality of life (QOL) among breast cancer patients (9).

Clinical Evidence related to Risk of Breast Cancer

Based on a total of 3 observational studies, black cohosh does not appear to increase the risk of developing breast cancer. Two studies found no significant association between use of black cohosh by post-menopausal women and breast cancer, hazard ratio (HR) 1.17 (95%CI 0.75-1.82) and adjusted odds ratio (AOR) 0.80 (0.63-1.00) (10, 11). One study found a significant 53% reduction in risk of breast cancer among post-menopausal women, OR 0.47 (0.27-0.82) (12).

Clinical Evidence related to Risk of Recurrence

Based on 1 observational study, black cohosh does not appear to increase risk of breast cancer recurrence. This study reported a 25% decreased risk of breast cancer recurrence associated with use of Remifemin in women with recent breast cancer and breast cancer survivors, HR 0.75 (0.63-0.89) (13). A total of 35.8% of Remifemin users were also taking tamoxifen, while 24.0% of non-users were taking tamoxifen. It is possible that the decreased risk of recurrence was due to higher rate of tamoxifen use or to use of Remifemin; however it appears that at least Remifemin may not interfere with the effect of tamoxifen. More research is needed to support this.

Clinical Evidence related to Estrogenic Effects

Based on 12 RCTs and 5 uncontrolled trials conducted in women without breast cancer (with the exception of one study), black cohosh does not appear to affect circulating levels of estradiol (E2), progesterone, luteinizing hormone (LH), or follicle stimulating hormone (FSH); or exert estrogen-like effects on tissues of the reproductive system (breast, endometrium, vaginal tissue) (5, 14-29). The exception to this was in two RCTs of women with infertility undergoing Clomid therapy who had increased estrogen levels with black cohosh, however in this situation this was considered a therapeutic outcome (19, 20). Black cohosh may exert estrogen like effect in bone, increasing bone formation and decreased bone resorption (18, 24, 29).

Adverse Events and Side Effects

Among breast cancer patients, there was no difference in rates of adverse events between patients receiving black cohosh and the control group. AE that were reported were generally mild in severity. Isolated adverse events that were reported in one trial included: one case of breast cancer recurrence and one hysterectomy among patients who were taking black cohosh and tamoxifen, however causality could not be inferred (5). In 2 RCTs, minor AE were reported but not described except as being inconsistent (5, 6).

Based on a review by Flower et al. including 17 controlled trials conducted among otherwise healthy women, there is no difference in the rate of adverse events among black cohosh users compared to subjects in the control groups (30). Most commonly reported AE included gastrointestinal upset, anxiety, irritability, and mood changes, as well as headaches.

There have been 21 case reports of hepatotoxicity associated with use of black cohosh products, however a causal relationship has not been established (31). There was no evidence of liver toxicity or elevated liver enzymes in the studies included in our review or that by Flower et al., with the exception of 2 cases of increased GGT reported out of the 17 controlled trials and 487 participants (30). A meta analysis of 5 RCTs found no impact on ALT, AST, and GGT (32). Nonetheless, caution is warranted in patients with a pre-existing liver condition.

Interactions with other Therapies, including Drugs and Natural Health Products

Based on the 3 RCTs and 2 uncontrolled trials cited above, there is no evidence of increased adverse events related to co-administration of tamoxifen and black cohosh. One observational study suggests that black cohosh may not interact negatively with tamoxifen, however more studies in this area are needed to confirm this (13).

One study in humans found that a very large dose of black cohosh (>1000mg; 40mg is the therapeutic dose) inhibited by 7% the enzyme CYP2D6, which is responsible for metabolizing tamoxifen to its active metabolite, endoxifen (33). The clinical relevance of this level of inhibition and this magnitude of dose is questionable but a theoretical possibility of interaction should be noted. Human trials co-administering black cohosh and tamoxifen in a clinical setting have not reported evidence of a negative interaction (see above).

Black cohosh does not appear to affect: CYP 1A2, CYP 2E1, CYP 3A4, CYP 3A5, or Pgp (33-36). The aromatase inhibitor anastrozole is primarily metabolized by CYP 3A4 (37).

Black cohosh does not appear to impact pharmacokinetics of digoxin in humans (36).

Cautions and Contraindications

Use with caution in patients with pre-existing liver conditions.

Dosing, frequency and length of treatment

40mg of a standardized extract daily for at least 3 months.

Disclaimer

The OICC, in collaboration with the CAMEO Research Program, has prepared this monograph, as part of a series of monograph development, to share results of a review of the research evidence related to common therapies and products used within cancer patient care. The following monograph is designed to provide evidence-based research and neither advocates for or against the use of a particular therapy. Every effort is made to ensure the information included in this monograph is accurate at the time it is published. Prior to using a new therapy or product, always consult a licensed health care provider. The information in this monograph should not be interpreted as medical advice nor should it replace the advice of a qualified health care provider.

References (An asterisk (*) denotes open-access articles)

- *1. Wolfe A, Wu S. Estrogen receptor-beta in the gonadotropin-releasing hormone neuron. *Semin Reprod Med.* 2012 Jan;30(1):23-31. PubMed PMID: 22271291. Epub 2012/01/25. eng.
2. Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V, Gorkow C, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? *Maturitas.* 2003;44 Suppl 1:S9-S20.
3. Powell SL, Godecke T, Nikolic D, Chen SN, Ahn S, Dietz B, et al. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. *J Agric Food Chem.* 2008 Dec 24;56(24):11718-26. PubMed PMID: 19049296. Epub 2008/12/04. eng.
- *4. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. *Journal of Clinical Oncology.* 2006;24(18):2836-41.
- *5. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. *Journal of Clinical Oncology.* 2001;19(10):2739-45.
6. Hernandez MG, Pluchino S. *Cimicifuga racemosa* for the treatment of hot flashes in women surviving breast cancer. *Maturitas.* 2003;44:Suppl-65.
7. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. *Cancer Investigation.* 2004;22(4):515-21.
8. Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch HH. Black cohosh (*Cimicifuga racemosa*) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study. *Gynecol Endocrinol.* 2011 Oct;27(10):844-8. PubMed PMID: 21231853. Epub 2011/01/15. eng.
- *9. Ma H, Carpenter CL, Sullivan-Halley J, Bernstein L. The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors - results of a prospective study. *BMC Cancer.* 2011;11:222.
- *10. Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. *Cancer Epidemiology, Biomarkers & Prevention.* 2010;19(7):1696-708.
- *11. Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study.[Erratum appears in *Cancer Epidemiol Biomarkers Prev.* 2009 Sep;18(9):2567]. *Cancer Epidemiology, Biomarkers & Prevention.* 2009;18(8):2207-13.
- *12. Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. *International Journal of Cancer.* 2007;120(7):1523-8.
13. Henneicke-von Zepelin HH, Meden H, Kostev K, Schroder-Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. *International Journal of Clinical Pharmacology and Therapeutics.* 2007;45(3):143-54.
14. Lundstrom E, Hirschberg AL, Soderqvist G. Digitized assessment of mammographic breast density - Effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. *Maturitas.* 2011 Sep 27. PubMed PMID: 21958943. Epub 2011/10/01. Eng.
- *15. Reame NE, Lukacs JL, Padmanabhan V, Eyvazzadeh AD, Smith YR, Zubieta JK. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. *Menopause.* 2008;15(5):832-40.
16. Ruhlen RL, Haubner J, Tracy JK, Zhu W, Ehya H, Lamberson WR, et al. Black cohosh does not exert an estrogenic effect on the breast. *Nutrition & Cancer.* 2007;59(2):269-77.
17. Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von SB. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. *Menopause.* 2007;14(1):89-96.
18. Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (*Actaea* or *Cimicifuga racemosa* extract) CR BNO 1055. *Menopause.* 2006;13(4):678-91.
19. Shahin AY, Ismail AM, Shaaban OM. Supplementation of clomiphene citrate cycles with *Cimicifuga racemosa* or ethinyl oestradiol--a randomized trial. *Reprod Biomed Online.* 2009 Oct;19(4):501-7. PubMed PMID: 19909590. Epub 2009/11/17. eng.
20. Shahin AY, Ismail AM, Zahran KM, Makhlof AM. Adding phytoestrogens to clomiphene induction in unexplained infertility patients--a randomized trial. *Reprod Biomed Online.* 2008 Apr;16(4):580-8. PubMed PMID: 18413068. Epub 2008/04/17. eng.
21. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. *Menopause.* 2008;15(1):51-8.
22. Rosic S, Kendic S, Becirevic A. The influence of sequential hormonal therapy on biochemical and cardiovascular indices in menopause. *Med Arh.* 2008;62(5-6):289-93.

23. Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. *Maturitas*. 2007;58(1):31-41.
24. Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (*Cimicifuga racemosa*) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. *Menopause*. 2006 Mar-Apr;13(2):185-96. PubMed PMID: 16645532. Epub 2006/04/29. eng.
25. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of *Cimicifuga racemosa* on climacteric complaints: a randomized study versus low-dose transdermal estradiol. *Gynecol Endocrinol*. 2005;20(1):30-5.
26. Liske E, Hanggi W, Henneicke-von Zepelin HH, Boblitz N, Wustenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (*Cimicifuga racemosa* rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. *J Womens Health Gend Based Med*. 2002 Mar;11(2):163-74. PubMed PMID: 11975864. Epub 2002/04/27. eng.
27. Duker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from *Cimicifuga racemosa* on gonadotropin release in menopausal women and ovariectomized rats. *Planta Med*. 1991 Oct;57(5):420-4. PubMed PMID: 1798794. Epub 1991/10/01. eng.
28. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. *Zentralbl Gynakol*. 1988;110(10):611-8.
29. Wuttke W, Seidlova-Wuttke D, Gorkow C. The *Cimicifuga* preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. *Maturitas*. 2003 Mar 14;44 Suppl 1:S67-77. PubMed PMID: 12609561. Epub 2003/03/01. eng.
30. Flower G, Fritz H, Seely D, Balneaves L. Black cohosh and menopausal hot flashes: a systematic review. Presented at AANP Convention, August 2012, Bellevue WA.
31. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. *Menopause*. 2010 Mar;17(2):426-40. PubMed PMID: 20216279. Epub 2010/03/11. eng.
32. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. *Menopause*. 2011 Apr;18(4):366-75. PubMed PMID: 21228727. Epub 2011/01/14. eng.
- *33. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther*. 2005 May;77(5):415-26. PubMed PMID: 15900287. Pubmed Central PMCID: 1894911. Epub 2005/05/19. eng.
- *34. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. *Integr Cancer Ther*. 2009 Sep;8(3):208-27. PubMed PMID: 19815591. Epub 2009/10/10. eng.
- *35. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. *J Clin Pharmacol*. 2006 Feb;46(2):201-13. PubMed PMID: 16432272. Pubmed Central PMCID: 1865122. Epub 2006/01/25. eng.
- *36. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, et al. Effect of milk thistle (*Silybum marianum*) and black cohosh (*Cimicifuga racemosa*) supplementation on digoxin pharmacokinetics in humans. *Drug Metab Dispos*. 2006 Jan;34(1):69-74. PubMed PMID: 16221754. Pubmed Central PMCID: 1868501. Epub 2005/10/14. eng.
- *37. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. *Br J Clin Pharmacol*. 2010 Dec;70(6):854-69. PubMed PMID: 21175441. Pubmed Central PMCID: 3014069. Epub 2010/12/24. eng.

Funding for this project was provided by the Canadian College of Naturopathic Medicine

